{"nctId":"NCT01396512","briefTitle":"Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers","startDateStruct":{"date":"2011-07"},"conditions":["Japanese Encephalitis","Japanese Encephalitis Virus Disease"],"count":274,"armGroups":[{"label":"IMOJEV™ Vaccine Group","type":"EXPERIMENTAL","interventionNames":["Biological: Live attenuated Japanese encephalitis chimeric virus vaccine"]},{"label":"CD.JEVAX ™ Vaccine Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)"]}],"interventions":[{"name":"Live attenuated Japanese encephalitis chimeric virus vaccine","otherNames":["IMOJEV™"]},{"name":"Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)","otherNames":["CD.JEVAX™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 12 to 24 months on the day of inclusion\n* In good general health, without significant medical history.\n* Provision of informed consent form signed by at least one parent or other legally acceptable representative.\n* Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.\n\nExclusion Criteria:\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.\n* Planned participation in another clinical trial during the present trial period.\n* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.\n* Known systemic hypersensitivity to any of IMOJEV™ components or history of a life-threatening reaction to a vaccine containing any of the same substances and vaccination,known systemic hypersensitivity to CD.JEVAX® main components and the other components (including Gelatin, kanamycin, and gentamicin).\n* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.\n* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.\n* Previous vaccination against flavivirus disease, including Japanese encephalitis (JE).\n* Administration of any anti-viral within 2 months preceding Visit 01 and up to the 4 weeks following the trial vaccination.\n* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.\n* Planned receipt of any vaccine from the inclusion up to the 4 weeks following the trial vaccination.\n* History of central nervous system disorder or disease, including seizures.\n* Planned receipt of any JE vaccine during the course of the study.\n* History of flavivirus infection (confirmed either clinically, serologically or virologically).\n* Administration of systemic corticosteroids for more than two consecutive weeks within the 4 weeks preceding vaccination.\n* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection 3 days before vaccination as well as the day of vaccination, according to Investigator judgment.\n* Thrombocytopenia or bleeding disorder contraindicated for vaccination with same administration route, or receipt of anticoagulants in the 3 weeks preceding inclusion.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","description":"Immunogenicity assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50). Seroconversion was defined as the percentage of participants who developed neutralizing antibody titers above 10 (1/dil) when seronegative at baseline (\\<1/10) or who presented a ≥4-fold rise in their neutralizing antibody titers when seropositive (≥1/10) at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","description":"Geometric mean titers were assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50).\n\nJE-CV PRNT50 antibody titer \\>10 (1/dil, Day 0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"908","spread":null},{"groupId":"OG001","value":"579","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroprotection Against Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","description":"Immunogenicity was assessed using a Japanese encephalitis chimeric virus (JE-CV) PRNT50 assay. Seroprotection was defined as the percentage of participants with a titer ≥10 (1/dil) at pre-vaccination and at Day 28 post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","description":"Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Loss, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling longest diameter ≥50 mm. Grade 3 systemic reactions: Fever \\>39.5°C; Vomiting ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - \\>3 hours; Drowsiness - sleeping most of the time or difficult to wake; Appetite Loss - refuses ≥3 feeds or most feeds; Irritability - inconsolable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":137},"commonTop":["Nasopharyngitis","Appetite Loss","Injection site Pain","Fever","Irritability"]}}}